Events Calendar

Mon
Tue
Wed
Thu
Fri
Sat
Sun
M
T
W
T
F
S
S
28
29
30
31
1
2
3
5
6
7
8
9
10
13
14
15
16
17
18
12:00 AM - Epic UGM 2025
19
20
21
22
23
24
25
26
27
28
29
30
31
The 2025 DirectTrust Annual Conference
2025-08-04 - 2025-08-07    
12:00 am
Three of the most interesting healthcare topics are going to be featured at the DirectTrust Annual conference this year: Interoperability, Identity, and Cybersecurity. These are [...]
ALS Nexus Event Recap and Overview
2025-08-11 - 2025-08-14    
12:00 am
International Conference on Wearable Medical Devices and Sensors
2025-08-12    
12:00 am
Conference Details: International Conference on Wearable Medical Devices and Sensors , on 12th Aug 2025 at New York, New York, USA . The key intention [...]
Epic UGM 2025
2025-08-18 - 2025-08-21    
12:00 am
The largest gathering of Epic Users at the Epic user conference in Verona. Generally highlighted by Epic’s keynote where she often makes big announcements about [...]
Events on 2025-08-04
Events on 2025-08-11
Events on 2025-08-18
Epic UGM 2025
18 Aug 25
Verona

Events

Latest News Press Releases

Jonathan Stein, Ph.D., HCLD(ABB), joins Tesis Labs as Chief Science Officer

jonathan stein attorney

Jonathan Stein, Ph.D., HCLD(ABB), joins Tesis Labs as Chief Science Officer

PHOENIX, – Tesis Labs, a leader in targeted genetic sequencing, has named life sciences lab veteran Jonathan Stein, Ph.D., HCLD(ABB), as the company’s first chief science officer and medical director.

Tesis uses a genetically integrated medical platform for targeted genetic sequencing and comprehensive genetic data collection to support many medical specialties. The company collaborates with hospitals, health systems, value-based care organizations, medical device companies, research organizations and others to offer next-generation genetic sequencing designed to improve patient care and quality outcomes.

As chief science officer, Dr. Stein will be responsible for assay development, budgeting, contracting, accreditation, staffing and supervision across the company’s diagnostics laboratories. Tesis currently has labs in Denver, Lafayette, Colo. and Houston and will be opening its new state of the art facility in Scottsdale, Ariz., in December 2021

“Dr. Stein’s extensive experience in genetics labs will be invaluable to us as we continue to expand our pipeline of new and innovative test panels,” said Ron King, chief executive officer of Tesis Labs. “He has a proven record as a chief science officer and hands-on lab researcher.”

Prior to joining Tesis Labs, Stein was chief science officer at Spectracell Laboratories in Houston, where he was responsible for project planning, quality assurance and regulatory compliance, assay development, and management. He also served as lab director for Spectracell before becoming CSO. In addition, Stein has worked as medical director and clinical consultant at Apex Molecular Laboratories, associate DNA lab director at Identigene, and research investigator at the University of Texas M.D. Anderson Cancer Center.

“Tesis is doing some amazing work and brings great energy and vision to the industry,” Dr. Stein said. “I have a solid background in next-generation sequencing, so the company’s strong focus on NGS made it an ideal fit.”

Dr. Stein received his Ph.D. in molecular and cancer genetics and holds a master’s degree in population and biomedical sciences from the University of Texas Health Science Center. He received a bachelor’s degree in biochemistry from the University of California, Santa Cruz.

For more information on Tesis Labs, visit www.tesislabs.com.

About Tesis Labs
Tesis Labs’ genetically integrated medical platform has revolutionized targeted genetic sequencing. Our mission is to change medicine by providing physicians, hospitals, and researchers with the tools to help patients treat and overcome major chronic conditions such as heart disease, lung disease, cancer, and diabetes through advanced genetic testing. Tesis offers healthcare providers and physicians access to our unique genetic testing and precision medicine, enabling them to create personalized care plans for treating chronic diseases – individually and across generations. We also enable medical device companies and pharmaceuticals to bring new products to market and create a robust repository of genetic data and research.